Shares of VBI Vaccines, Inc. – (NASDAQ:VBIV) traded up 5.3% during trading on Thursday . The stock traded as high as $3.80 and last traded at $3.77, with a volume of 63,884 shares changing hands. The stock had previously closed at $3.58.

Separately, Ladenburg Thalmann assumed coverage on VBI Vaccines, Inc. – in a report on Tuesday. They issued a “buy” rating on the stock.

The firm’s market cap is $124.24 million. The company’s 50 day moving average is $3.88 and its 200 day moving average is $3.95.

An institutional investor recently bought a new position in VBI Vaccines, Inc. – stock. Cambridge Investment Research Advisors Inc. acquired a new stake in VBI Vaccines, Inc. – (NASDAQ:VBIV) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,433,100 shares of the biopharmaceutical company’s stock, valued at approximately $3,497,000. Cambridge Investment Research Advisors Inc. owned approximately 6.09% of VBI Vaccines, Inc. – as of its most recent SEC filing.

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.